The Global Alzheimer's Disease Therapeutics and Diagnostics Market to Progress with 5.56% of CAGR by 2028

Triton Market Research presents the Global Alzheimer's Disease Therapeutics and Diagnostics Market report segmented by Therapeutics and Diagnostics (Therapeutics {Therapeutics by Drugs [Marketed Drugs, Pipeline Drugs], Therapeutics by Disease Stage [Late Stage: Severe AD, Early/Middle Stage: Mild to Moderate AD, Prodromal Stage], Therapeutics by Generic and Branded [Branded, Generic]}, Diagnostics {Lumbar Puncture Test, Positron Emission Tomography (PET), Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Blood Test, Other Diagnostics}) and by Geographical Region (North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa), discussing Market Summary, Industry Outlook, Key Insights, Impact of COVID-19, Porter's Five Forces Analysis, Key Buying Impact Analysis, Industry Components, Different Phases Of Alzheimer's Disease, Market Attractiveness Index, Vendor Scorecard, Key Strategic Developments, Drivers, Challenges, Opportunities, Competitive Landscape, Research Methodology & Scope, Global Market Size, Forecasts & Analysis (2021-2028).

Triton Market Research, in its report on the Global Alzheimer's Disease Therapeutics and Diagnostics Market, implies that this industry is expected to progress at a CAGR of 5.56% during the forecasting period (2021-2028).

Request a Free Sample Report @ https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market#request-free-sample

As per estimates, nearly 5.8 million people in the United States have Alzheimer's dementia. By 2050, this number is expected to rise to 13.8 million. Thus, the growing prevalence of dementia in developing countries is a major factor that is expected to fuel the growth of the market in the coming years.

However, the failure of the late-stage drugs to induce significant improvement of symptoms and stringent regulations regarding drug development and clinical trials are hampering the market growth process.

The market in North America currently leads the global market, with the largest share. It is expected to continue its stronghold in the years to come. There is a high population comprising elderly adults present in the region, who form a major patient base for dementia and Alzheimer's. This has led to an increased demand for AD therapeutics and diagnostics here.

Moreover, there are several research studies being conducted in the US for the development of novel therapeutics and diagnostics for the disease, which are being supported by new product launches. For instance, C2N Diagnostics launched PrecivityAD in November 2020, which is the world's first blood test to measure amyloid levels in the blood for Alzheimer's diagnosis. All these factors are anticipated to boost the studied market growth in the region.

Sun Pharmaceuticals Industries Ltd, Zydus Cadila, Allergan Plc acquired by Abbvie, Biogen Inc, Pfizer Inc, Teva Pharmaceutical Industries Limited, Luye Pharma Group, GE Healthcare, Eli Lilly & Company, Cognoptix Inc, Eisai Co Ltd, Amarantus Bioscience Holdings Inc, Siemens Healthineers AG, Novartis AG, F Hoffmann La Roche, Lupin Limited, Merck & Co Inc, Baxter International Inc, PeopleBio Co, and Johnson & Johnson are the eminent players present in this market.

The competition among players in this industry has increased significantly with the introduction of generics. Furthermore, this industry is also observing meaningful strategic collaborations among different players. For instance, Johnson & Johnson and GE Healthcare have formed entered into a partnership for a project that aims to find pre-symptomatic biomarkers for AD. Recent developments with respect to regulatory guidelines and disease biomarkers are expected to open new gateways for innovation in this field, which is expected to generate opportunities for new players to step into this market.

Read More @ https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market

Purchase this report @ https://www.tritonmarketresearch.com/reports/alzheimers-disease-therapeutics-and-diagnostic-market#purchase-option

Triton Market Research
196, wards wharf approach
London E16 2EQ
Phone: +44 7441 911839
Email: sales@tritonmarketresearch.com
Website: https://www.tritonmarketresearch.com/

We are a leading market research company with offices in the UK, providing the best online market research and data search reports to our clients.

This release was published on openPR.